New research by David Holtzman, M.D. at the Washington University School of Medicine points to a sleep regulation protein in the brain as a possible target for Alzheimer's disease treatment or prevention. The protein, called orexin, plays a role in rousing the brain from sleep.
Matthew Szulik, 58, of Boston has always put his family first. Despite building a reputation as one of the most innovative and creative technology entrepreneurs in the world, New Bedford, Massachusetts, native Szulik left his job to care for a family member with Alzheimer’s.
Sherry Sharp, wife of CarMax founder Richard L. Sharp, today announced that she has agreed to serve on Cure Alzheimer’s Fund’s Board of Directors. In her husband’s honor, she is going to do everything she can to further our mission to fund research with the highest probability of preventing, slowing, or reversing Alzheimer’s disease through venture-based philanthropy.
Recent months have witnessed three remarkable developments in projects supported by Cure Alzheimer’s Fund.
From the age of 2, when he disassembled his brother’s mechanical duck and his father praised him for his curiosity, Charlie Glabe was always interested in the way things work. Today, Charlie is a highly respected neuroscientist and a member of the Cure Alzheimer’s Fund Research Consortium.
“For the first time, and to the astonishment of many of their colleagues, researchers created what they call Alzheimer’s in a Dish — a petri dish with human brain cells that develop the telltale structures of Alzheimer’s disease.”
Cure Alzheimer's Fund is saddened by the recent passing of Stephen F. Heinemann, a pioneer in brain disease research and a former member of our Scientific Advisory Board. Dr. Heinemann, who was based at the Salk Institute for Biological Studies, passed away earlier this month at age 75.
A new "alternative amyloid hypothesis” from the lab of Dr. Charles Glabe, at the University of California at Irvine, helps explain precisely how neurons (nerve cells) die in Alzheimer’s disease and how known genetic mutations initiate a chain reaction in this long process. The important new hypothesis was driven by research supported by Cure Alzheimer’s Fund, and has just been being published in the Journal Neurobiology of Disease. Dr.
A promising first-in-class drug stimulates the creation of new nerve cells in the brains of Alzheimer's mice and will soon be tested in the brains of human patients, thanks to new research by Dr. Sam Gandy, member of Cure Alzheimer's Fund's Research Consortium, at Mount Sinai School of Medicine in New York.
A prestigious new list of the "World's Most Influential Scientific Minds" includes 16 scientists closely associated with Cure Alzheimer's Fund.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.